Avalon Pharmaceuticals, Inc. has entered a drug discovery, development and commercialization collaboration with Merck & Co. to identify and develop inhibitors for an undisclosed target related to the development of cancer. Avalon will use its AvalonRx platform to screen a select set of compounds from Merck’s compound library and identify hits against this target that is referred to as “intractable” based on the difficulty in identifying inhibitors. Avalon will select c...